Moat Investing Nuances – Pat Dorsey artwork

Moat Investing Nuances – Pat Dorsey

Capital Allocators – Inside the Institutional Investment Industry

July 6, 2026

Pat Dorsey is the Founder of Dorsey Asset Management, a $1.7 billion global public equity manager focused on companies with competitive advantages and long investment runways.
Speakers: Pat Dorsey, Ted Seides
**Pat Dorsey** (0:00)
Switching costs can cut both ways, because if you have high customer switching costs, then probably your competitors do too. It's hard to get people to switch. You have trouble growing in the high switching cost industries a lot of times. Network effects are often held up as the end-all, be-all of Moats. But network effects can degrade. People leave the network, the value of the community diminishes, the distinction between radial networks, like Western Union or nodal networks. It's complicated.
That's honestly one of the fun things about it is that over time, everything in investing develop pattern recognition. The great traders that you read about in Money Masters, they develop pattern recognition. I've seen this macro story before and here's how it usually plays out. So I'm going to make this bet. Analyzing competitive advantage is the same thing. The more companies you look at, the more likely you are to say, okay, I think there's something here. Then you try to think through why is it a government approval, is it a switching cost, is it scale economies? There's some foundational attribute that enables the company to withstand competition, defy the laws of economic gravity, sustain high returns on capital in a competitive world where both in theory and empirically, most companies don't do that. Most companies do revert over time to cost capital.

**Ted Seides** (1:23)
I'm Ted Seides, and this is Capital Allocators.
My guest on today's show is Pat Dorsey, the founder of Dorsey Asset Management, a $1.7 billion global public equity manager focused on companies with competitive advantages and long investment runways. Pat created Morningstar's Moat Research framework and led its equity research efforts for a dozen years before launching his firm in 2014
Our conversation covers the nuances of investing in businesses with wide moats across quantitative analysis, switching costs, network effects, brands, management, alignment, capital allocation, and reinvestment runways. We then turn to Pat's application of moat analysis to his investing, including concentration, global scope, position sizing, decision making, and lessons learned.
Before we get going, long-time listeners might remember my discussion of the lived experience of Joseph Campbell's Hero's Journey, created by Michael Mirvosh and described in episode 402 two years ago. Well, after an eight-year sabbatical, I'll soon return to the mountains of West Virginia for my next journey. I'll take leave of my familiar surroundings and electronic devices to go on a week-long adventure, meeting allies, facing ordeals, and encountering the so-called belly of the beast. After which, I'll return transformed by the experience. Like my past journeys, I have no idea what I'll find or learn once I arrive. And that is the essence and beauty of the experience. If you also feel the call to adventure, there's still time to engage and sign up. Hop on heroesjourneyfoundation.org to learn more about the upcoming journey. Hope to see you on the mount. And thanks for spreading the word about the Heroes Journey and Capital Allocators. Capital Allocators is brought to you by AlphaSense. Here's something for you. Most AI tools today are very good at sounding right. But can you actually trace it back to a filing transcript or a specific passage that drove the answer? Or are you just trusting the confidence of the output? For allocators, that's not a minor concern. Amidst filing, incorrect source, or context that gets lost somewhere in the retrieval chain, aren't edge cases. They're how decisions go wrong. AlphaSense is the AI platform built specifically for this. They own the content, over 500 million curated documents, from broker research and expert transcripts to filings and earnings calls. And they own the retrieval layer on top of it. That means every answer can link back to an exact verifiable source. Because the answer is only as good as what's underneath it. And with AlphaSense, you know exactly what that is. See it for yourself. Try a free trial at alphasense.com/capital.
That's alphasense.com with a hyphen in the middle slash capital. Capital Allocators is also brought to you by Long Angle. I spend my days talking with people allocating serious capital. What I found is that even the most sophisticated investors want a place to compare notes, privately, with peers at the same stage. That's Long Angle, a vetted community of 8,000 high-net-worth individuals. Members have committed over $420 million across private equity, venture, real estate, energy, search funds, and litigation finance. Institutional offerings with full diligence materials on every opportunity. No membership fees, and you can apply at longangle.com/capital.
Capital Allocators is also brought to you by Admired Leadership. Back in April on episode 497, I sat down with Randall Studman, the executive coach behind Admired Leadership, who has advised more than 500 CEOs, including some of the most respected names in asset management. Randall introduced me to Alex, an AI leadership coach's team built on 40 years of proprietary research into what the best leaders actually do. For investment professionals, that means your entire team gets on-demand coaching grounded in the behaviors that drive results and build the kind of followership that retains your top talent.

61 more minutes of transcript below

Feed this to your agent

Try it now — copy, paste, done:

curl -H "x-api-key: pt_demo" \
  https://spoken.md/transcripts/1000651996090

Works with Claude, ChatGPT, Cursor, and any agent that makes HTTP calls.

From $0.10 per transcript. No subscription. Credits never expire.

Using your own key:

curl -H "x-api-key: YOUR_KEY" \
  https://spoken.md/transcripts/1000775612649